Determination of picogram levels of midazolam, and 1-and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry

被引:34
作者
Eap, CB [1 ]
Bouchoux, G
Golay, KP
Baumann, P
机构
[1] Hop Cery, Dept Univ Psychiat Adulte, Unite Biochim & Psychopharmacol Clin, CH-1008 Lausanne, Switzerland
[2] Ecole Polytech, Dept Chim, Lab Mecan React, F-91128 Palaiseau, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 802卷 / 02期
基金
新加坡国家研究基金会;
关键词
midazolam; hydroxymidazolam;
D O I
10.1016/j.jchromb.2003.12.014
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Midazolam is a widely accepted probe for phenotyping cytochrome P4503A. A gas chromatography-mass spectrometry (GC-MS)-negative chemical ionization method is presented which allows measuring very low levels of midazolam (MID), 1-OH midazolam (1OHMID) and 4-OH midazolarn (4OHMID), in plasma, after derivatization with the reagent N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide. The standard curves were linear over a working range of 20 pg/ml to 5 ng/ml for the three compounds, with the mean coefficients of correlation of the calibration curves (n = 6) being 0.999 for MID and 1OHMID, and 1.0 for 4OHMID. The mean recoveries measured at 100 pg/ml, 500 pg/ml, and 2 ng/ml, ranged from 76 to 87% for MID, from 76 to 99% for 1OHMID, from 68 to 84% for 4OHMID, and from 82 to 109% for N-ethyloxazepam (internal standard). Intra- (n = 7) and inter-day (n = 8) coefficients of variation determined at three concentrations ranged from 1 to 8% for MID, from 2 to 13% for IOHMID and from 1 to 14% for 4OHMID. The percent theoretical concentrations (accuracy) were within +/-8% for MID and 1OHMID, within +/-9% for 4OHMID at 500 pg/ml and 2 ng/ml, and within +/-28% for 4OHMID at 100 pg/ml. The limits of quantitation were found to be 10 pg/ml for the three compounds. This method can be used for phenotyping cytochrome P4503A in humans following the administration of a very low oral dose of midazolam (75 mug), without central nervous system side-effects. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 17 条
[1]   Rifampin drastically reduces plasma concentrations and effects of oral midazolam [J].
Backman, JT ;
Olkkola, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :7-13
[2]   Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A [J].
Carrillo, JA ;
Ramos, SI ;
Agundez, JAG ;
Martinez, C ;
Benitez, J .
THERAPEUTIC DRUG MONITORING, 1998, 20 (03) :319-324
[3]   Pharmacokinetics and metabolism of intravenous midazolam in preterm infants [J].
de Wildt, SN ;
Kearns, GL ;
Hop, WCJ ;
Murry, DJ ;
Abdel-Rahman, SM ;
van den Anker, JN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (06) :525-531
[4]  
HEIZMANN P, 1983, BR J CLIN PHARM, V16, P43
[5]   Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam [J].
Kashuba, ADM ;
Bertino, JS ;
Rocci, ML ;
Kulawy, RW ;
Beck, DJ ;
Nafziger, AN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :269-277
[6]   Sensitive and specific determination of midazolam and 1-hydroxymidazolam in human serum by liquid chromatography-electrospray mass spectrometry [J].
Marquet, P ;
Baudin, O ;
Gaulier, JM ;
Lacassie, E ;
Dupuy, JL ;
Francois, B ;
Lachâtre, G .
JOURNAL OF CHROMATOGRAPHY B, 1999, 734 (01) :137-144
[7]   Simultaneous determination of midazolam and its metabolites 1-hydroxymidazolam and 4-hydroxymidazolam in human serum using gas chromatography mass spectrometry [J].
Martens, J ;
Banditt, P .
JOURNAL OF CHROMATOGRAPHY B, 1997, 692 (01) :95-100
[8]   Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity [J].
McCrea, J ;
Prueksaritanont, T ;
Gertz, BJ ;
Carides, A ;
Gillen, L ;
Antonello, S ;
Brucker, MJ ;
Miller-Stein, C ;
Osborne, B ;
Waldman, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (12) :1212-1220
[9]   First-pass metabolism of midazolam by the human intestine [J].
Paine, MF ;
Shen, DD ;
Kunze, KL ;
Perkins, JD ;
Marsh, CL ;
McVicar, JP ;
Barr, DM ;
Gillies, BS ;
Thummel, KE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :14-24
[10]   The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration [J].
Reed, MD ;
Rodarte, A ;
Blumer, JL ;
Khoo, KC ;
Akbari, B ;
Pou, S ;
Kearns, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (12) :1359-1369